Skip to main content

Company News for May 14, 2025

Zacks Investment Research - Wed May 14, 2025
Company News for May 14, 2025
  • Shares of Under Armour, Inc. (UAA) gained 1% after the company reported fourth-quarter fiscal 2025 loss of $0.08 per share, narrower than the Zacks Consensus Estimate of a loss of $0.09 per share. 
  • Landstar System, Inc.’s (LSTR) shares declined 2.5% after the company reported first-quarter 2025 earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.92 per share. 
  • Shares of Silicon Laboratories Inc. (SLAB) jumped 5.7% after the company reported first-quarter 2025 loss of $0.08 per share, narrower than the Zacks Consensus Estimate of a loss of $0.09 per share.
  • CG Oncology, Inc.’s (CGON) shares declined 3.9% after the company reported first-quarter 2025 loss of $0.45 per share, broader than the Zacks Consensus Estimate of a loss of $0.39 per share. 

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Silicon Laboratories, Inc. (SLAB): Free Stock Analysis Report
 
Landstar System, Inc. (LSTR): Free Stock Analysis Report
 
Under Armour, Inc. (UAA): Free Stock Analysis Report
 
CG Oncology, Inc. (CGON): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.